uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market
The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.
The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.